Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.
The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | David Happel |
Contact Details
Address: 155 Bovet Road, Suite 303 San Mateo, California 94402 United States | |
| Phone | 650 561 8600 |
| Website | sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001400118 |
| CUSIP Number | 786681102 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President and Director |
| Elizabeth Rozek Esq., J.D. | Chief Legal and Administrative Officer |
| Urs Greber Ph.D. | Co-Founder |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Thierry Chauche | Chief Financial Officer and Principal Accounting Officer |
| Dr. Marie O'Farrell Ph.D. | Chief Scientific Officer |
| Robert D'Urso | Senior Vice President of New Products |
| Dr. Andreas Grauer M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 8-K | Current Report |
| May 12, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 28, 2026 | 424B5 | Filing |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 21, 2026 | ARS | Filing |
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |